128441-15-6Relevant academic research and scientific papers
THE NOVEL REDUCTION OF PYRIDINE DERIVATIVES WITH SAMARIUM DIIODIDE
Kamochi, Yasuko,Kudo, Tadahiro
, p. 2383 - 2396 (1993)
Pyridine was rapidly reduced into piperidine with samarium diiodide in the presence of water at room temperature in excellent yield.On the similar reactions of pyridine derivatives bearing chloro, amino and cyano functionalities with samarium diiodide-H2O-THF system, these functionalities were partly eliminated with this system to afford pyridine or piperidine.Furthermore, pyridinecarboxamides were reduced with this system to give the corresponding methylpyridines and 2-pyridinecarboxylic acid was reduced to give 2-methylpyridine as the major products.
One-pot synthesis of cyclohexylamine and: N -aryl pyrroles via hydrogenation of nitroarenes over the Pd0.5Ru0.5-PVP catalyst
Chaudhari, Chandan,Sato, Katsutoshi,Ikeda, Yasuyuki,Terada, Kenji,Abe, Naoya,Nagaoka, Katsutoshi
supporting information, p. 9743 - 9746 (2021/06/15)
The direct synthesis of cyclohexylamine via the hydrogenation of nitrobenzene over monometallic (Pd, Ru or Rh) and bimetallic (PdxRu1-x) catalysts was studied. The Pd0.5Ru0.5-PVP catalyst was the most effective catalyst for this reaction. The catalyst can be reused and applied for the synthesis of N-aryl pyrroles and quinoxalines from nitrobenzenes.
Substituted xanthine compound and its preparation and use (by machine translation)
-
Paragraph 0213; 0214; 0217; 0218, (2018/09/26)
The invention discloses substituted xanthine compounds, a preparation method and applications thereof, and specifically relates to compounds represented by the formula (I), stereo isomers and pharmaceutically acceptable salts thereof, wherein the R1 and R2 are defined in the description. The invention also relates to a pharmaceutical composition containing the compounds, an application of the pharmaceutical composition in preparation of drugs for treating diseases or symptoms caused by high activity of DPP-IV or overexpression of DPP-IV, and a method using the pharmaceutical composition to treat related diseases. The provided compounds can effectively inhibit the activity of DPP-IV.
Novel chiral derivatizing agents for 1H NMR determination of enantiomeric purities of carboxylic acids
Wada, Koji,Goto, Mizuko,Yamashita, Hiroshi,Nagasawa, Kazuo
, p. 964 - 978 (2017/06/13)
(S)-4-(3-Aminopyrrolidin-1-yl)coumarin (1), (S)-4-(3-aminopiperidin-1-yl)coumarin (4), and (S)-4-(3-aminoazepan-1-yl)coumarin (7), prepared from 4-chlorocoumarin and (S)-pyrrolidin-3-amine, (S)-piperidin-3-amine, and (S)-azepan-3-amine, respectively, were proven to be versatile and reliable 1H NMR optical purity determination agents for chiral carboxylic acids.
Dielectrically controlled resolution (DCR) of 3-aminopiperidine via diastereomeric salt formation with N-tosyl-(S)-phenylalanine
Sakurai, Rumiko,Sakai, Kenichi,Kodama, Koichi,Yamaura, Masanori
experimental part, p. 221 - 224 (2012/06/15)
A useful key intermediate for the dipeptidyl peptidase-4 (DPP-4) inhibitor, 3-aminopiperidine 1, was successfully resolved with an enantiomerically pure resolving agent, N-tosyl-(S)-phenylalanine 2, to give both stereoisomers (R)-1 and (S)-1 as a less-sol
A protection strategy substantially enhances rate and enantioselectivity in ω-transaminase-catalyzed kinetic resolutions
Hoehne, Matthias,Robins, Karen,Bornscheuer, Uwe T.
body text, p. 807 - 812 (2009/04/10)
The kinetic resolution of 3-aminopyrrolidine (3AP) and 3-aminopiperidine (3APi) with ω-transaminases was facilitated by the application of a protecting group concept. 1-N-Cbz-protected 3-aminopyrrolidine could be resolved with >99% ee at 50% conversion, the resolution of 1-N-Boc-3-aminopiperidine yielded 96% ee at 55% conversion. The reaction rate was up to 50-fold higher by using protected substrates. Most importantly, enantioselectivity increased remarkably after carbamate protection compared to the unprotected substrates (86 vs. 99% ee). Surprisingly, benzyl protection of 3AP had no influence on enantioselectivity. A possible explanation for this observation could be the different flexibility of the benzyl- or carbamate-protected 3AP as confirmed by NMR spectroscopy.
8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS
-
Page/Page column 3, (2008/06/13)
The invention relates to 8-[3-amino-piperidin-1-yl]-xanthines and the physiologically acceptable salts thereof, particularly the hydrochlorides thereof.
METHOD FOR PRODUCING 3-AMINOPIPERIDINE DIASTEREOMER
-
Page/Page column 4-5, (2008/06/13)
A method for increasing the enantiomeric purity of a desired enantiomer of 3- aminopiperidine comprising: providing a composition containing (i?)-3-arninopiperidine and (jS)-3-aminopiperidine; combining the composition with a resolving agent selected from
METHOD FOR PRODUCING CHIRAL 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES
-
Page/Page column 6-7, (2008/06/13)
The invention relates to an improved method for producing enantiomer-free 8-(3-amino-piperidin-1-yl)-xanthines.
Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part III: Synthesis of potent antagonists with αvβ3/α IIbβ3 dual activity and improved water solubility
Ishikawa, Minoru,Hiraiwa, Yukiko,Kubota, Dai,Tsushima, Masaki,Watanabe, Takashi,Murakami, Shoichi,Ouchi, Shokichi,Ajito, Keiichi
, p. 2131 - 2150 (2007/10/03)
In order to optimize our novel integrin αvβ 3/αIIbβ3 dual antagonists, spatial screening at the N-terminus was performed. The αvβ 3 antagonistic activity varied depending on the space that was occupied by the N-terminus, but high potency against αIIbβ 3 was well maintained. The (3S)-aminopiperidine analogue had the strongest activity against αvβ3, and the S isomer at piperidine was more potent than the R isomer. Compounds selected on the basis of SAR analysis of a novel lead compound showed acceptable early absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles and sufficient water solubility for use as infusion drugs. Docking studies with the αvβ3 receptor were performed to confirm the SAR findings.
